Published in J Chromatogr A on April 14, 2009
The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol (2013) 1.67
p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol (2010) 1.66
p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol (2009) 1.36
Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol (2013) 1.10
p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol (2013) 1.04
Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. BMC Nephrol (2014) 0.88
Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis. Toxins (Basel) (2015) 0.86
Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand. PLoS One (2014) 0.83
An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis. J Mater Sci Mater Med (2014) 0.82
p-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis. Korean J Pediatr (2013) 0.78
Heritability and clinical determinants of serum indoxyl sulfate and p-cresyl sulfate, candidate biomarkers of the human microbiome enterotype. PLoS One (2014) 0.77
Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function. Perit Dial Int (2013) 0.77
Is Fluorescence Valid to Monitor Removal of Protein Bound Uremic Solutes in Dialysis? PLoS One (2016) 0.75
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study. Microbiome (2016) 0.75
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med (2004) 6.52
Intrarenal resistive index after renal transplantation. N Engl J Med (2013) 4.19
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36
The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis (2009) 2.34
Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol (2005) 2.29
Late referral of patients with chronic kidney disease: no time to waste. Mayo Clin Proc (2006) 2.04
Colonic contribution to uremic solutes. J Am Soc Nephrol (2011) 1.98
Fluorescent indicators based on BODIPY. Chem Soc Rev (2011) 1.94
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl (2009) 1.83
Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int (2004) 1.78
Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant (2004) 1.75
Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant (2012) 1.71
p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol (2010) 1.66
Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol (2005) 1.66
Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant (2008) 1.63
The histology of kidney transplant failure: a long-term follow-up study. Transplantation (2014) 1.61
Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol (2009) 1.51
Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation (2010) 1.45
Impact of vascular calcification on corrected QT interval at the time of renal transplantation. Am J Nephrol (2011) 1.42
Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii. Appl Environ Microbiol (2006) 1.36
p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol (2009) 1.36
Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides, and xylooligosaccharides. Crit Rev Food Sci Nutr (2011) 1.36
Influence of genetic background on albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice. Am J Physiol Renal Physiol (2009) 1.36
Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem (2005) 1.35
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation (2006) 1.33
p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant (2009) 1.26
Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol (2009) 1.24
New insights into uremic toxicity. Curr Opin Nephrol Hypertens (2008) 1.21
Functional analysis of colonic bacterial metabolism: relevant to health? Am J Physiol Gastrointest Liver Physiol (2011) 1.21
The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol (2012) 1.21
Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care (2006) 1.21
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol (2010) 1.21
Romosozumab in postmenopausal women with osteopenia. N Engl J Med (2014) 1.18
Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis (2009) 1.18
Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol (2007) 1.17
Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int (2003) 1.17
Relevance of protein fermentation to gut health. Mol Nutr Food Res (2011) 1.15
Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med (2003) 1.14
A microwave-assisted click chemistry synthesis of 1,4-disubstituted 1,2,3-triazoles via a copper(I)-catalyzed three-component reaction. Org Lett (2004) 1.13
Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant (2011) 1.12
Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol (2006) 1.12
Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther (2004) 1.12
A review of albumin binding in CKD. Am J Kidney Dis (2008) 1.11
Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg (2008) 1.11
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem (2008) 1.10
Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol (2013) 1.10
The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant (2011) 1.10
Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant (2005) 1.09
Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol (2008) 1.07
Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet (2004) 1.06
Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis (2004) 1.06
Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation (2003) 1.06
Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int (2003) 1.06
A highly potassium-selective ratiometric fluorescent indicator based on BODIPY azacrown ether excitable with visible light. Org Lett (2005) 1.03
Functionalisation of fluorescent BODIPY dyes by nucleophilic substitution. Chem Commun (Camb) (2005) 1.03
Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis (2009) 1.03
First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging (2006) 1.03
Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation (2010) 1.02
Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. Biopharm Drug Dispos (2013) 1.01
Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest (2004) 1.01
Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol (2013) 1.01
Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol (2010) 1.00
The value of tuberculin skin testing in haemodialysis patients. Nephrol Dial Transplant (2004) 0.99
Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif Organs (2006) 0.99
Reductive demetallation of Cu-corroles--a new protective strategy towards functional free-base corroles. Org Biomol Chem (2008) 0.98
Dialysis cannot be dosed. Semin Dial (2011) 0.98
Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int (2005) 0.98
High rate of Charcot foot attacks early after simultaneous pancreas-kidney transplantation. Transplantation (2007) 0.97
Calcium metabolism in the early posttransplantation period. Clin J Am Soc Nephrol (2009) 0.97
Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab (2013) 0.97
Searching for uremic toxins. Clin J Am Soc Nephrol (2012) 0.97
The colon: an overlooked site for therapeutics in dialysis patients. Semin Dial (2013) 0.97
Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int (2013) 0.96
Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflamm Bowel Dis (2011) 0.96
Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol Dial Transplant (2011) 0.95